Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $2
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $3 to $2.
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and lowers the price target from $3 to $2.